Molecular biological studies have created a new understanding of medulloblastomas, revealing key cell signaling pathways that promote tumor growth. These studies have identified molecular markers that can serve as prognostic indicators and which will provide therapeutic targets in the very near future. In contrast to conventional histological techniques, molecular biological methods are designed to detect highly unstable molecules degraded by conventional tissue collection and fixation protocols. Consequently, a new approach to tissue collection is required for molecular analysis as we enter the next era of brain tumor therapy.

Packer RJ, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690–698.
Louis DN, Pomeroy SL, Cairncross JG: Focus on central nervous system neoplasia. Cancer Cell 2002;1:125–128.
Biegel JA, et al: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74–79.
Segal RA, et al: Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994;91:12867–12871.
Kim JY, et al: Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711–719.
Pomeroy SL, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436–442.
Gilbertson RJ, et al: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272–3280.
Grotzer MA, et al: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027–1035.
Grotzer MA, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425–2433.
Thiesing JT, et al: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96:3195–3199.
McLaughlin M, et al: Marked regression of a metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec). J Pediatr Hematol Oncol, in press.
Johnson RL, et al: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668–1671.
Hahn H, et al: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841–851.
Marigo V, et al: Biochemical evidence that patched is the Hedgehog receptor. Nature 1996;384:176–179.
Wechsler-Reya RJ, Scott MP: Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999;22:103–114.
Pietsch T, et al: Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085–2088.
Raffel C, et al: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842–845.
Dong J, et al: Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat 2000;16:89–90.
Taylor MD, et al: Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306–310.
Hamilton SR, et al: The molecular basis of Turcot’s syndrome. N Engl J Med 1995;332:839–847.
Huang H, et al: APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433–437.
Koch A, et al: Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445–449.
Yokota N, et al: Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 2002;101:198–201.
Zurawel RH, et al: Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896–899.
Taipale J, et al: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005–1009.
Berman DM, et al: Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559–1561.
Willert J, et al: A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002;2:8.
Lawinger P, et al: The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med 2000;6:826–831.
Fruhwald MC, et al: Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas – Implications for tumor biology and potential clinical utility. Oncogene 2001;20:5033–5042.
Lusher ME, et al: Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 2002;62:5906–5911.
Zuzak TJ, et al: Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer 2002;38:83–91.
Rood BR, et al: Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 2002;62:3794–3797.
Segal RA, Pomeroy SL, Stiles CD: Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci 1995;15:4970–4981.
MacDonald TJ, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143–152.
Gilbertson R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705–712.
Hernan R, et al: ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140–148.
Ambartsumian NS, et al: Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996;13:1621–1630.
Davies MP, et al: Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996;13:1631–1637.
Del Valle L, et al: Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002;8:1822–1830.
Eberhart CG, et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36–44.
Herms J, et al: c-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395–402.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.